122 related articles for article (PubMed ID: 15451528)
1. The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles.
Dillen K; Weyenberg W; Vandervoort J; Ludwig A
Eur J Pharm Biopharm; 2004 Nov; 58(3):539-49. PubMed ID: 15451528
[TBL] [Abstract][Full Text] [Related]
2. The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D,L-lactide-glycolide) nanoparticles.
Bozdag S; Dillen K; Vandervoort J; Ludwig A
J Pharm Pharmacol; 2005 Jun; 57(6):699-707. PubMed ID: 15969924
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
Dillen K; Vandervoort J; Van den Mooter G; Ludwig A
Int J Pharm; 2006 May; 314(1):72-82. PubMed ID: 16600538
[TBL] [Abstract][Full Text] [Related]
4. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
Mainardes RM; Evangelista RC
Int J Pharm; 2005 Feb; 290(1-2):137-44. PubMed ID: 15664139
[TBL] [Abstract][Full Text] [Related]
5. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
6. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
Kumar PS; Ramakrishna S; Saini TR; Diwan PV
Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
[TBL] [Abstract][Full Text] [Related]
7. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.
Choi SH; Park TG
Int J Pharm; 2006 Mar; 311(1-2):223-8. PubMed ID: 16423477
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F
Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
Jeong YI; Na HS; Seo DH; Kim DG; Lee HC; Jang MK; Na SK; Roh SH; Kim SI; Nah JW
Int J Pharm; 2008 Mar; 352(1-2):317-23. PubMed ID: 18160236
[TBL] [Abstract][Full Text] [Related]
10. Preparation factors affecting the properties of polylactide nanoparticles: a factorial design study.
Vandervoort J; Ludwig A
Pharmazie; 2001 Jun; 56(6):484-8. PubMed ID: 11446170
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
12. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
13. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
Singh J; Pandit S; Bramwell VW; Alpar HO
Methods; 2006 Feb; 38(2):96-105. PubMed ID: 16442811
[TBL] [Abstract][Full Text] [Related]
14. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
15. Influence of post-emulsification drying processes on the microencapsulation of human serum albumin.
Lane ME; Brennan FS; Corrigan OI
Int J Pharm; 2006 Jan; 307(1):16-22. PubMed ID: 16274944
[TBL] [Abstract][Full Text] [Related]
16. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
Budhian A; Siegel SJ; Winey KI
Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
[TBL] [Abstract][Full Text] [Related]
17. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method.
Mao S; Shi Y; Li L; Xu J; Schaper A; Kissel T
Eur J Pharm Biopharm; 2008 Feb; 68(2):214-23. PubMed ID: 17651954
[TBL] [Abstract][Full Text] [Related]
18. Radiosterilisation of indomethacin PLGA/PEG-derivative microspheres: protective effects of low temperature during gamma-irradiation.
Fernández-Carballido A; Puebla P; Herrero-Vanrell R; Pastoriza P
Int J Pharm; 2006 Apr; 313(1-2):129-35. PubMed ID: 16495023
[TBL] [Abstract][Full Text] [Related]
19. Design and optimization of NSAID loaded nanoparticles.
Sashmal S; Mukherjee S; Ray S; Thakur RS; Ghosh LK; Gupta BK
Pak J Pharm Sci; 2007 Apr; 20(2):157-62. PubMed ID: 17416573
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
